DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
PGNY logo

Progyny, Inc. Stock Price

NasdaqGS:PGNY Community·US$2.1b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 55 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

PGNY Share Price Performance

US$27.35
5.22 (23.59%)
​
US$33.82
Fair Value
US$27.35
5.22 (23.59%)
19.1% undervalued intrinsic discount
US$33.82
Fair Value
Price US$27.35
AnalystConsensusTarget US$33.82
AnalystLowTarget US$30.00
AnalystHighTarget US$40.00
Tue, 11 Aug 26
Fair ValueUS$33.82
Share Pricen/a

PGNY Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$33.82 19.1% undervalued intrinsic discount

Rising Demand For Women's Health Will Transform Market Opportunity

0users have liked this narrative
0users have commented on this narrative
26users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$30 8.8% undervalued intrinsic discount

Tightening US Healthcare Policies And Gig Shifts Will Dampen Prospects

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$40 31.6% undervalued intrinsic discount

Delayed Parenthood And Healthcare Consumerism Will Boost Fertility Ecosystem

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
PGNY logo
Progyny
19.1% undervalued intrinsic discount

Rising Demand For Women's Health Will Transform Market Opportunity

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 11 Aug
Read Narrative
PGNY logo
Progyny
8.8% undervalued intrinsic discount

Tightening US Healthcare Policies And Gig Shifts Will Dampen Prospects

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 25 Aug
Read Narrative
PGNY logo
Progyny
31.6% undervalued intrinsic discount

Delayed Parenthood And Healthcare Consumerism Will Boost Fertility Ecosystem

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 28 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
PGNY logo

PGNY: Future Utilization And Renewal Trends Will Support Policy Tailwinds

Fair Value: US$30 8.8% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
PGNY logo

PGNY: Client Renewals And Conservative Guidance Will Drive Future Share Upside

Fair Value: US$33.82 19.1% undervalued intrinsic discount
26 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
PGNY logo

PGNY: Fertility Utilization Trends And Guidance Are Expected To Support Upside

Fair Value: US$40 31.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet and undervalued.

0 Risks
4 Rewards
View Full Analysis

Progyny, Inc. Key Details

US$1.3b

Revenue

US$988.7m

Cost of Revenue

US$322.1m

Gross Profit

US$243.5m

Other Expenses

US$78.6m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
1.02
24.57%
6.00%
0%
View Full Analysis

About PGNY

Founded
2008
Employees
846
CEO
Peter Anevski
WebsiteView website
www.progyny.com

Progyny, Inc., a benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Recent PGNY News & Updates

Seeking Alpha • Sep 05

Progyny: Slow But Consistent Growth With A Pristine Balance Sheet

Summary Progyny, Inc. offers fertility benefits management, growing eligible members to 7.2 million and posting steady revenue and EPS growth. PGNY reported Q2 revenues of $350.5M (+5.3% YoY) and guided FY revenue to $1.36–$1.385B, with non-GAAP EPS of $2.04–$2.10. Shares trade at just under 13x FY2026E EPS, supported by a net cash balance and $142.5M remaining on its repurchase authorization. An updated analysis around this slow-growth name with a pristine balance sheet follows in the paragraphs below. Read the full article on Seeking Alpha

Recent updates

No updates

Progyny, Inc. Competitors

PEN logo

Penumbra

Symbol: NYSE:PEN
Market cap: US$12.5b
BAX logo

Baxter International

Symbol: NYSE:BAX
Market cap: US$12.3b
BTSG logo

BrightSpring Health Services

Symbol: NasdaqGS:BTSG
Market cap: US$12.2b
EHC logo

Encompass Health

Symbol: NYSE:EHC
Market cap: US$12.0b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide